Loading
DFP-11207 is an experimental small molecule from Delta-Fly Pharma, in phase 1 trials for solid tumours; its current status is not stated.
DFP-11207 is a small molecule (oral, modified 5-FU) from Delta-Fly Pharma. An improved oral 5-FU designed to keep anti-tumour activity without causing a low platelet count. Its furthest stage is phase 1, for solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT02171221 in solid tumours COMPLETED; no later registered trial found. Whether it works in people has not been established unless a trial below reports it.
An improved oral 5-FU designed to keep anti-tumour activity without causing a low platelet count.
1.DFP-11207 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"DFP-11207" OR ABSTRACT:"DFP-11207") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DFP-11207, not a curated reading list.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Delta-Fly Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Delta-Fly Pharma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/